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Abstract: The increase in hospitalization due to acute bacterial skin and skin structure 
infections (ABSSSI) caused by resistant pathogens supports the need for new treatment 
options. Antimicrobial options for ABSSSI that provide broad-spectrum coverage, including 
gram-negative pathogens and multidrug-resistant gram-positive bacteria, such as methicillin-
resistant Staphylococcus aureus (MRSA), are limited. Delafloxacin is a novel fluoroquinolone 
available as intravenous and oral formulations and is characterized by an increased efficacy in 
acidic environments and activity on bacterial biofilm. Delafloxacin displays enhanced in vitro 
activity against MRSA, and enterococci, while maintaining efficacy against gram-negative 
pathogens and anaerobes. Delafloxacin has been studied for the treatment of ABSSSI and 
respiratory infections. Phase III studies have demonstrated noninferiority of delafloxacin 
compared to vancomycin, linezolid, tigecycline, and the combination of vancomycin plus 
aztreonam in the treatment of ABSSSI. Due to its favorable pharmacokinetic characteristics, 
the wide spectrum of action, and the potential for sequential therapy, delafloxacin represents 
a promising option in the empirical and targeted treatment of ABSSSI, both in hospital- and 
in community-based care.
Keywords: bacterial skin and skin structure infections, multidrug-resistant bacteria, methicillin-
resistant Staphylococcus aureus, delafloxacin
Current scenario of complicated skin and soft 
tissue infections
The clinical spectrum of skin infections is highly variable and ranges from mild forms 
to life-threatening diseases.1 Among these, acute bacterial skin and skin structure infec-
tions (ABSSSI), formerly referred to as complicated skin and soft tissue infections, 
represent a frequent reason for hospital admission and a common cause of morbidity 
in the community.2,3 A nearly 3-fold increase in ABSSSI visit rates had been docu-
mented among patients presenting to the emergency departments with skin abscesses 
and cellulitis in the USA.2,4
Staphylococcus aureus represents the most common cause of ABSSSI, and 
methicillin-resistant S. aureus (MRSA) is often the most frequently isolated pathogen 
in complicated forms.3,5 In Europe, despite a high variability in prevalence, MRSA 
isolation can reach up to 25% in ABSSSI, especially in those areas where antimicro-
bial resistance represents a concern (e.g., Italy, Greece, and Eastern Europe).6,7 In the 
USA, community-acquired (CA) MRSA strains are endemic and frequently associated 
with skin infections and purulent skin abscesses, with reported outbreaks in military 
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recruits, athletes, and prisoners.8,9 MRSA prevalence among 
patients with ABSSSI undergoing microbiological cultures 
was reported as high as 75%–80% in the USA.3,10,11
The increase in hospital admissions required to treat 
ABSSSI with intravenous (IV) antibiotics along with the 
spread of multidrug-resistant (MDR) bacteria have caused a 
considerable impact on hospital stay and patient’s morbidity, 
reinforcing the need for new treatment options.12
New therapeutic options for the treatment of ABSSSI 
have recently become available and offer advantages such 
as MRSA coverage as well as the possibility for outpa-
tient treatment (e.g., IV to oral switch and/or infrequent 
administration).13
New therapeutic options for 
complicated skin and soft tissue 
infections
Antimicrobials that are commonly used in the treatment of 
ABSSSI due to methicillin-susceptible S. aureus (MSSA) 
include beta-lactams, especially oxacillin and flucloxacillin, 
fluoroquinolones (e.g., moxifloxacin and levofloxacin), and 
clindamycin.1 MRSA is suspected in the presence of several 
risk factors, including nosocomial or health care-associated 
infection, previous MRSA infection or colonization, recent 
exposure to antimicrobial agents, and abscesses.14,15
Vancomycin has been considered for decades as the 
drug of choice for ABSSSI caused by MRSA. In two Euro-
pean surveys documenting the choices of antibiotics for 
the  treatment of ABSSSI, vancomycin was found to be the 
most used antimicrobial in both 2010 and 2015.16,17 Various 
studies, however, have now highlighted that vancomycin 
presents several limitations in the treatment of MRSA. First, a 
progressive increase in vancomycin minimum inhibitory con-
centrations (MICs) over the years was observed in S. aureus 
and was associated with less favorable clinical outcomes 
compared to isolates with MIC below 1 mg/L.18 Second, a 
decreased efficacy of vancomycin has been documented in 
severe infections caused by MSSA compared to MRSA.19,20 
Third, in order to achieve adequate plasmatic concentrations, 
therapeutic drug monitoring is needed to minimize the risk 
of nephrotoxicity.21 Finally, vancomycin requires twice-daily 
IV administration, limiting the possibility for outpatient 
parenteral antibiotic therapy.
Several novel therapeutic options have become available 
for the treatment of ABSSSI caused by MDR bacteria, includ-
ing strains with increased vancomycin MICs (Table 1).13
Data on the efficacy of new agents for ABSSSI are mainly 
derived from noninferiority trials and do not directly  compare 
the efficacy of newer compounds. Nevertheless, several 
characteristics of newly studied molecules appear promising 
for ABSSSI treatment, including wide spectrum of action, 
favorable pharmacokinetics (PK) and pharmacodynamics, 
and high tolerability.13
Characteristics and limitations of the molecules that are 
currently available and under investigation for the treatment 
of ABSSSI are reported in Table 1.
Table 1 Characteristics of antimicrobials that are available or in late stage of development for the treatment of ABSSSI
Bactericidal  
activity
Prolonged  
half-life
MRSA 
activity
Equal activity on 
MRSA and MSSA
Oral and IV 
formulation
Gram-negative  
activity
Ideal drug Yes Yes Yes Yes Yes Yes
Available for use
Oxacillin Yes No No No Yes Limited
Moxifloxacin Yes Yes (OD) No No Yes Moderate
Levofloxacin Yes No No No Yes Moderate
Trimethoprim/
sulfamethoxazole
Yes No Yes/No No Yes Limited
Clindamycin Yes No Yes/No No Yes Limited
Daptomycin Yes Yes (OD) Yes Yes No No
Tigecycline No No Yes Yes No Yes
Vancomycin Yes No Yes No No No
Linezolid No No Yes Yes Yes No
Ceftaroline Yes No Yes Yes No Moderate
Dalbavancin Yes Yes (OW) Yes Yes No No
Oritavancin Yes Yes (OW) Yes Yes No No
Tedizolid No Yes (OD) Yes Yes Yes No
Phase III trials completed
Telavancin Yes Yes (OD) Yes Yes No No
Delafloxacin Yes No Yes Yes Yes Yes
Abbreviations: ABSSSI, acute bacterial skin and skin structure infections; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus 
aureus; OD, once daily; OW, once weekly.
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Delafloxacin
Newer quinolones and delafloxacin
Delafloxacin belongs to the quinolone class of antibiotics, 
synthetic antimicrobials developed in the 1960s. The quino-
lones exert their activity by generating a complex between 
a DNA molecule and two enzymes (e.g., DNA gyrase and 
topoisomerase IV), thus inhibiting bacterial DNA supercoiling 
and synthesis.22,23 Since the discovery of nalidixic acid, the 
first quinolone agent produced, several new agents have been 
manufactured by alteration of the bicyclic quinolone ring. 
Specifically, the addition of fluorine to the chemical structure 
led to the generation of the widely used fluoroquinolones (e.g., 
ciprofloxacin, levofloxacin, moxifloxacin, and so on), charac-
terized by a wider antibacterial spectrum compared to the first 
generation of quinolones.24 Resistance to ciprofloxacin and 
levofloxacin, however, has developed starting from the 1990s, 
especially among gram-negative bacteria, thus becoming a 
prevalent clinical issue that is threatening the efficacy of these 
drugs.25 Studies analyzing the relationship between quinolone 
structure and activity have led to the development of new 
agents targeting both gyrase and topoisomerase IV, broaden-
ing the spectrum of activity against gram-positive and gram-
negative bacteria and overcoming antimicrobial resistance.26 
Five new quinolones are currently undergoing clinical testing, 
including delafloxacin (WQ-3034), avarofloxacin (JNJ-Q2), 
zabofloxacin (DW224a), finafloxacin (BAY35-3377), and 
non-fluorinated nemonoxacin (TG-873870).23
Here, we review the characteristics and potential use of 
delafloxacin in clinical practice.
Chemical structure and properties
Delafloxacin has a molecular weight of 440.763 g/mol and 
presents a larger molecular surface compared to other quino-
lones due to a heteroaromatic substitution at N-1. Delafloxa-
cin presents a weak acid character caused by the absence of 
the strongly basic C-7 group that is typical of the quinolone 
structure. Furthermore, this molecule is characterized by a 
strong electron-withdrawing effect on the aromatic ring due 
to the presence of a chlorine atom at C-8 position.27 Chemical 
structure of delafloxacin is presented in Figure 1.
At neutral pH, delafloxacin exists in a deprotonated form, 
and its anionic structure appears to enhance its potency in 
an acidic environment.28 Due to these characteristics, dela-
floxacin activity in low pH environment including phagoly-
sosomes, inflammatory cells, and infected tissues appears 
unique compared to older molecules.27,28 Furthermore, the 
risk for resistant strain selection is reduced and the activity 
toward fluoroquinolones nonsusceptible strains is enhanced 
by delafloxacin’s dual mechanism of action toward both DNA 
gyrase and topoisomerase IV.29
Delafloxacin spectrum of activity
Delafloxacin displays a broad spectrum of activity against a 
variety of gram-positive pathogens, while maintaining activ-
ity against gram-negative bacteria and anaerobes.30 Compared 
to other quinolones such as levofloxacin and ciprofloxacin, 
delafloxacin has displayed greater in vitro activity against 
both quinolone-susceptible and quinolone-resistant gram-
positive pathogens, including MSSA, MRSA, Streptococcus 
pyogenes, and enterococci.31 Against quinolone-susceptible 
Streptococcus pneumoniae, delafloxacin showed MIC
90
 of 
0.015 μg/mL and was 32-, 64-, and 128-fold more effective 
than moxifloxacin, levofloxacin, and ciprofloxacin, respec-
tively. Against quinolone-resistant strains of S. pneumoniae, 
the MIC
90
 of delafloxacin was 0.12 μg/mL compared to MIC
90
 
of 8, 16, and 64 μg/mL for trovafloxacin, levofloxacin, and 
ciprofloxacin, respectively.31
Delafloxacin has an excellent in vitro activity against 
staphylococci, showing MIC
90 
ranging from 0.12 to 0.5 
μg/mL for MRSA and 0.25 μg/mL for coagulase-negative 
staphylococci.27,31 Compared with moxifloxacin, delafloxacin 
showed superiority toward both levofloxacin-susceptible and 
levofloxacin-resistant MRSA strains. The in vitro activity 
of delafloxacin compared to levofloxacin and ciprofloxacin 
was recently reported from two global Phase III studies 
investigating 685 S. aureus isolates. According to Clinical 
and Laboratory Standards Institute breakpoints. 34% of S. 
aureus isolates were levofloxacin resistant. The delafloxacin 
MIC
90
 value against levofloxacin-nonsusceptible S. aureus, 
MRSA, and MSSA isolates was 0.25 μg/mL.32
Delafloxacin was more active than other quinolones 
against quinolone-susceptible enterococci, showing MIC
90
 
for Enterococcus faecalis of 0.03 μg/mL and an MIC
50
 for 
Enterococcus faecium of 0.25 μg/mL.31
Figure 1 Chemical structure of delafloxacin.
Notes: Three characteristics differentiate delafloxacin from other quinolones: 
1) the lack of a protonable substituent group in position 7 that confers a weak 
acid character to the molecule; 2) the presence of a chlorine atom in position 8 
that reduces the reactivity of the heterocycle, stabilizing the molecule; and 3) the 
aromatic ring attached to N1 that increases the surface of the molecule.
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Against quinolone-susceptible Enterobacteriaceae, 
delafloxacin showed comparable activity to levofloxacin and 
ciprofloxacin, while increased activity was shown against 
quinolone-resistant strains of Haemophilus influenzae, 
Moraxella catarrhalis, Legionella spp., Pseudomonas aeru-
ginosa, and Helicobacter pylori.33
Delafloxacin is active against microorganisms respon-
sible for sexually transmitted diseases, such as Chlamydia 
trachomatis, Ureaplasma urealyticum, and Mycoplasma 
hominis. Low MICs have also been shown against Neisseria 
gonorrhoeae, including ciprofloxacin-resistant strains.34,35
Delafloxacin activity in acidic 
environments and on biofilm
In acidic environments, the activity of delafloxacin appears 
enhanced.36 In a study including 35 strains of S. aureus with 
clinically relevant resistance mechanisms, delafloxacin 
showed significantly lower MICs (3–5 log
2
 dilutions) com-
pared to moxifloxacin. Delafloxacin’s superiority was further 
enhanced at lower pH (pH 5.5) with the MIC decreasing by 5 
log
2
 dilutions. Compared to moxifloxacin, whose activity is 
reduced by the acidic pH present in vacuolar subcellular com-
partments, accumulation of delafloxacin increased 10-fold 
in bacteria and at an intracellular level. These data support 
the use of delafloxacin for the treatment of staphylococcal 
infections in acidic environments such as biofilm-associated 
infections and abscesses. In these environments, antibiotics 
have usually reduced activity. Delafloxacin use could be 
promising in other environments characterized by acidic pH, 
such as skin and urinary infections.36
Against the strains of Enterobacteriaceae collected from 
patients with urinary tract infection with pH of 6.5 or less, 
MICs of delafloxacin were 2- to 5-fold lower than those of 
ciprofloxacin.37
Besides its direct antibacterial effect, the inhibition of 
S. aureus biofilm production has also been documented.38 
Due to the acidic environment within biofilms, delafloxacin 
activity can be enhanced, such that it shows superiority 
compared to other compounds and similar activity of that 
of daptomycin. Delafloxacin was able to reduce bacterial 
viability of over 50% against both MSSA and MRSA, was 
able to decrease biofilm depth, and appeared more potent 
compared to daptomycin against MRSA strains.38
Delafloxacin PK
Hoover et al summarized the pharmacokinetic properties, 
safety, and tolerability of single and multiple doses of IV 
delafloxacin through three Phase I clinical trials, including 
two randomized, double-blind, placebo-controlled studies 
and one open-label, randomized, crossover study.39 In the 
first study, single ascending doses of IV delafloxacin (from 
300 to 1200 mg) were administered to 62 healthy volunteers 
(52 active, 10 placebo). In the second study, IV delafloxacin 
was given to 12 healthy volunteers (8 active, 4 placebo) as 
a single dose of 300 mg on day 1, followed by twice-daily 
dosing on day 2 through day 14. In the third two-period, 
two-sequence study, 56 healthy volunteers were randomly 
assigned to one of two sequences of a single oral dose of 
delafloxacin (450 mg tablet) or IV delafloxacin (300 mg) 
in order to determine the absolute bioavailability of the oral 
formulation of delafloxacin.
Overall, the three studies encompassed 94 healthy 
volunteers and showed that delafloxacin’s half-life ranged 
from 8.2 to 17.7 hours (with a mean half-life of 12 hours) 
and had a dose-independent volume of distribution (V
d
) 
of ~35 L (range, 30.2–38.5 L). Delafloxacin C
max
 and area 
under the concentration–time curve (AUC) values increased 
proportionally and more than proportionally with increasing 
doses, respectively.39
Accumulation of delafloxacin appeared minimal after 
multiple doses, showing an accumulation ratio of 1.09 after 
14 days of twice-daily IV administration of 300 mg. Mean 
delafloxacin renal clearance was comparable on day 1 (14.1 
L/hour) and day 14 (13.8 L/hour).39
Delafloxacin undergoes minimal oxidative metabolism 
and has a renal excretion predominantly (65%). A mass bal-
ance study using radiolabeled delafloxacin in healthy male 
volunteers studied the excretion of delafloxacin after a single 
300 mg IV dose.40 Overall, 66% of the dose was recovered in 
the urine, mainly as unchanged delafloxacin. Approximately 
29% was recovered in the feces due to biliary excretion and/
or transintestinal elimination.
Delafloxacin plasma protein binding (mainly albumin) 
was ~84% and was not significantly affected by renal impair-
ment.41 A double-blind, placebo-controlled, Phase I clinical trial 
investigated the effect of sex and age on delafloxacin PK. The 
results showed that delafloxacin PK was comparable in men 
and women, while significantly higher C
max
 and AUC
0–∞
 were 
observed in elderly compared to younger patients, probably 
due to different creatinine clearance values among groups.42
Renal impairment appeared to significantly affect dela-
floxacin clearance. A dosage reduction to 200 mg IV every 
12 hours is recommended in the presence of severe renal 
impairment (creatinine clearance <30 mL/min).43
A Phase I, open-label study investigated the PK and safety 
of a single IV dose of 300 mg delafloxacin in 18 subjects with 
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mild, moderate, and severe hepatic impairment (Child–Pugh 
class A, B, and C, respectively) compared with 18 healthy 
controls.44 Mean delafloxacin AUC
0–∞
, C
max
, exposure, and 
clearance among patients with liver impairment did not 
significantly differ from the healthy subjects. Based on these 
data, dose adjustment of delafloxacin in patients with hepatic 
impairment is not needed.
Delafloxacin drug–drug interactions
In vitro studies confirmed that delafloxacin does not exert 
inhibitory effects on hepatic enzymes, except for a mild 
induction of CYP3A4 enzymes. A Phase I study encompass-
ing 22 healthy subjects investigated the clinical relevance 
of delafloxacin drug interactions on CYP3A4. Two doses 
of midazolam were administered in the absence and after 6 
days of delafloxacin treatment (450 mg every 12 hours). The 
24-hour AUCs of midazolam and its metabolite did not dif-
fer before and after delafloxacin administration, suggesting 
that delafloxacin does not have clinically relevant effects on 
cytochrome P450 3A4.45
Clinical efficacy
Animal models
Studies on animal models identified the AUC/MIC ratio as the 
most reliable parameter to predict delafloxacin efficacy.46,47 A 
murine model of lung infection including MRSA, penicillin-
resistant S. pneumoniae, and ESBL-producing Klebsiella 
pneumoniae investigated the efficacy of delafloxacin adminis-
tered IV (300 mg) or orally (450 mg) twice daily. The results 
confirmed the efficacy of delafloxacin on resistant strains.46
Clinical studies
Delafloxacin has been approved by the US Food and Drug 
Administration for the treatment of ABSSSI in June 2017. 
Two Phase II and two Phase III trials have analyzed the 
efficacy of delafloxacin vs comparators in these infections 
(Table 2).
A Phase II, double-blind clinical trial compared two doses 
of delafloxacin (300 and 450 mg IV every 12 hours) with tige-
cycline (100 mg IV followed by 50 mg every 12 hours) admin-
istered for 5–14 days in 150 patients with ABSSSI including 
cellulitis, abscesses, and wound infections.48 S. aureus was 
isolated in 86.5% of cases, of which ~70% were MRSA 
and 63% were levofloxacin-resistant strains. Cure rates were 
94.3%, 92.5%, and 91.2% among patients treated with dela-
floxacin 300 mg every 12 hours, delafloxacin 450 mg every 
12 hours, and tigecycline 50 mg every 12 hours, respectively.48
Another Phase II trial was conducted in a population of 
256 adult patients with ABSSSI including cellulitis (45%), 
abscesses (28.5%), wound infections (25%), and burns 
(1.5%) to evaluate the efficacy of IV delafloxacin compared 
to linezolid and vancomycin.49 Delafloxacin cure rate was 
70.4% and was comparable to linezolid (64.9%) and signifi-
cantly higher than vancomycin (54.1%, p=0.03). Clinical cure 
rates were similar in the group of patients with MRSA infec-
tions, while higher cure rates were achieved by delafloxacin 
among patients with body mass index ≥30 kg/m2.49
Two Phase III studies, defined as PROCEED, encompass-
ing 660 and 860 patients with ABSSSI and comparing dela-
floxacin with vancomycin plus aztreonam have been recently 
concluded.50,51 The studies analyzed the efficacy and microbio-
logical response of delafloxacin among subjects with various 
infections including resistant S. aureus and gram-negative 
pathogens. Patients received delafloxacin 300 mg IV every 
12 hours or delafloxacin 300 mg IV every 12 hours for 3 days 
with a mandatory blinded switch to oral delafloxacin 450 mg 
every 12 hours or vancomycin 15 mg/kg IV with aztreonam 
between 5 and 14 days. In both studies, the primary European 
Medicines Agency (EMA) endpoint was the reduction of 
lesion size in the first 48–72 hours and the clinical response 
Table 2 Phase II and III clinical trials analyzing the efficacy of IV delafloxacin in ABSSSI
Study type Patients (n) Delafloxacin arm Comparator(s) Outcome Reference
Phase II 150 Two IV doses (300 
and 450 mg q12h)
Tigecycline (100 mg first 
dose, then 50 mg q12h)
Cure rates: 94.3% delafloxacin 300 mg, 
92.5% 450 mg, 91.2% tigecycline
48
Phase II 256 300 mg q12h Linezolid (600 mg IV q12h); 
vancomycin (15 mg/kg q12h)
Cure rates: 70.4% delafloxacin, 64.9% 
linezolid, 54.1% vancomycin
49
Phase III 660 300 mg q12h Vancomycin (15 mg/kg q12h) 
± aztreonam
Objective response: 78.2% delafloxacin, 
80.9% vancomycin/aztreonam
Investigator-assessed cure: 52.0% 
delafloxacin, 50.5% vancomycin/
aztreonam
Late follow-up: 70.4% delafloxacin, 
66.6% vancomycin/aztreonam
57
Abbreviations: ABSSSI, acute bacterial skin and skin structure infections; IV, intravenous; q12h, every 12 hours.
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at 28 days. Evaluation of outcomes occurred at 14 and 
21–28 days (late follow-up). Compared to the combination 
of vancomycin plus aztreonam, delafloxacin demonstrated 
noninferiority in reducing lesion size at the primary infection 
site at 48–72 hours. Delafloxacin showed noninferiority on 
assessment of signs and symptoms of infection at the follow-
up visit. The outcome of delafloxacin treatment in patients 
with ABSSSI due to gram-negative pathogens (97 patients, 
19%) has been recently reported. 52 K. pneumoniae was the 
most frequent gram-negative isolate (MIC
50
, MIC
90
, and MIC 
ranges were 0.12, 0.25, and 0.03–4 μg/mL, respectively). 
Clinical response rates among patients treated with delafloxa-
cin compared to vancomycin/aztreonam at 48–72 hours, day 
14, and day 21–28 were 85.6% vs 88.3%, 98.7% vs 97.6%, 
and 97.3% vs 97.4%, respectively. Among gram-positive 
infections (n=987), objective response rates at 48–72 hours, 
day 14, and day 21–28 were 87.9% vs 87%, 97.9% vs 98.1%, 
and 97.2% vs 97.5% in the delafloxacin and comparator arms, 
respectively.53 Microbiological eradication rates for infections 
due to MRSA were 98.1% and 98.0% for patients treated with 
delafloxacin and vancomycin, respectively.
Delafloxacin is also under investigation for respiratory 
infections. A Phase II trial in acute exacerbation of COPD 
demonstrated comparable efficacy to levofloxacin. Delafloxa-
cin is currently being studied in CA pneumonia in comparison 
to moxifloxacin.54,55
Delafloxacin safety
Phase I studies have shown that the occurrence of adverse 
effects (AEs) is associated with delafloxacin dose. In the 
dose escalation study, IV delafloxacin doses of 800 mg or 
more were associated with adverse reactions in over 50% 
of the participants.42 AEs were mainly gastrointestinal (e.g., 
diarrhea). Oral administration of delafloxacin, however, was 
well tolerated across the dose range (from 50 to 1600 mg).
In the Phase II trial comparing two doses of delafloxa-
cin and tigecycline in ABSSSI, the administration of IV 
delafloxacin 300 mg every 12 hours was not associated 
with significant drug toxicity.48 AEs, mainly nausea and IV 
infusion-related effects, were more frequent among patients 
receiving tigecycline and high delafloxacin dose (450 mg 
every 12 hours). In this study, delafloxacin appeared to be 
associated with a decrease in glucose plasma levels, although 
this AE has not been confirmed by other trials.
In the comparative study of delafloxacin, linezolid, and 
vancomycin in treating ABSSSI, the highest number of AEs 
was reported in the delafloxacin arm (74.4% compared to 
72% for linezolid and 64.6% for vancomycin).49 Nausea 
was the most frequent AE. Two cases of elevation of the 
alanine transaminase and aspartate transaminase levels 
were reported (one in the delafloxacin and the other in the 
vancomycin group).
Delafloxacin showed a similar tolerability profile to 
vancomycin/aztreonam in patients with ABSSSI according 
to the two recent registrational Phase III trials.56,57 Rates of 
treatment-emergent AEs were similar in patients receiv-
ing delafloxacin to those receiving vancomycin/aztreonam 
(47.7% vs 45.1%, respectively). Gastrointestinal-related 
events including nausea (4.3% vs 6.1%, respectively) and 
diarrhea (2.0% vs 6.1%, respectively) were the most com-
mon treatment-emergent AEs reported. Discontinuation 
of treatment was reported in 2.4% of patients receiving 
vancomycin/aztreonam and in 0.8% of patients receiving 
delafloxacin. Serious AEs were similar in the delafloxacin and 
vancomycin/aztreonam groups (3.6% vs 3.5%, respectively). 
No treatment-related deaths were reported in the studies.56
To date, no safety study has reported cases of Clostridium 
difficile diarrhea associated with delafloxacin use. This could 
be related to delafloxacin activity against anaerobes, showing 
MICs below 0.015 g/mL against C. difficile.31
No AEs at the level of central nervous system, ten-
dons muscles, joints, and nerves have been reported. No 
clinically relevant phototoxicity has been demonstrated for 
delafloxacin.58
A randomized, double-blind, placebo-controlled, four-
period, crossover study in 52 healthy adults assessed the 
effect of delafloxacin administered at 300 and 900 mg IV 
compared to moxifloxacin on the corrected QT interval. No 
positive relationship between delafloxacin plasma concentra-
tions and corrected QT was demonstrated.59
Delafloxacin use in clinical practice
Similar to other fluoroquinolones, delafloxacin presents 
favorable PK/pharmacodynamics characteristics (e.g., high 
volume of distribution, good bioavailability) along with a 
bactericidal activity against both gram-positive and gram-
negative pathogens, representing an attractive option for use 
in clinical practice.
Unique characteristics of delafloxacin include an 
extended spectrum of activity against MRSA and anaerobes, 
the enhanced activity in acidic environments, and a favorable 
tolerability profile demonstrated in clinical trials (Table 3).
Delafloxacin in ABSSSI
Delafloxacin represents a promising option in the empirical 
and targeted treatment of ABSSSI, including cellulitis, skin 
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abscesses, and secondary infections such as surgical or burn 
wound infections and diabetic foot infections.
Efficacy of delafloxacin in ABSSSI has been validated 
by Phase II and III trials showing comparable activity to 
linezolid, tigecycline, and vancomycin for the treatment of 
MDR gram-positive bacteria, including MRSA, and vanco-
mycin/aztreonam against gram-negative bacteria. Compared 
to vancomycin, delafloxacin appeared more active among 
obese patients.
The activity against mixed gram-positive and gram-
negative infections makes delafloxacin a very attractive 
option for the treatment of ABSSSI in patients with multiple 
comorbidities who are at risk of developing polymicrobial 
infections. Compared to other antibiotics with activity against 
polymicrobial ABSSSI, such as tigecycline, delafloxacin 
presents the potential for oral switch, allowing for early 
patient discharge, and activity against P. aeruginosa that 
can be associated with ABSSSI in selected populations (e.g., 
patients with diabetes, burn wound infections). Furthermore, 
compared to linezolid and tigecycline that exhibit bacterio-
static activity, delafloxacin acts as a bactericidal agent.
In diabetic foot infections, moxifloxacin has been found 
to maintain antimicrobial concentrations above MIC in the 
perinecrotic tissue, thus proving its effectiveness in patients 
with extensive ischemic involvement or large ulcers. Similar 
to moxifloxacin, delafloxacin represents a promising option 
in these infections due to its diffusion in acidic environments 
and its broad spectrum of activity.60,61 Furthermore, the high 
bone concentrations displayed by quinolones in general and 
delafloxacin diffusion through the biofilm support further 
investigation on the use of delafloxacin in ABSSSI compli-
cated by osteomyelitis or bone infections, including pros-
thetic joint infections.62 In these settings, where prolonged 
antimicrobial treatment is usually required, delafloxacin may 
represent an attractive alternative due to the availability of an 
oral formulation and a favorable safety profile.
Delafloxacin use in other infections
High pulmonary diffusion (including high penetration in 
the epithelial lining fluid) along with delafloxacin increased 
 efficacy against MRSA and anaerobes justify its use in 
respiratory infections, including nosocomial pnemonia 
and pulmonary abscesses.46,63 So far, delafloxacin has been 
 successful in treating COPD exacerbations in comparison with 
levofloxacin and is currently being tested in CA pneumonia 
with moxifloxacin or linezolid as comparators.54,55
The high concentration of quinolones in the urinary tract 
and prostate tissue makes delafloxacin a potential option for 
sequential therapy of complicated urinary tract infections and 
prostatitis, which may require prolonged treatment.64
Finally, similar to other quinolones such as moxifloxacin, 
delafloxacin presents a wide spectrum of action and high 
tissue penetration with lipid solubility and diffusion in acid 
media, thus supporting a potential role in the treatment of 
complicated intra-abdominal infections.65
Conclusion
Delafloxacin is a new quinolone characterized by a broad 
spectrum of activity against gram-positive pathogens, such 
as MRSA, and gram-negative bacteria including quinolone-
resistant Escherichia coli and K. pneumoniae. Delafloxacin 
has the potential to be used in sequential therapy due to the 
availability of an oral formulation. Clinical studies have dem-
onstrated excellent results in the treatment of ABSSSI against 
heterogeneous bacterial populations, showing similar efficacy 
to comparators such as vancomycin, linezolid, and tigecycline. 
New studies are ongoing to support the use of delafloxacin in 
various infections, while real-world data are awaited to con-
solidate delafloxacin use as the empirical and targeted therapy 
of ABSSSI, both in the community and in nosocomial settings.
Disclosure
The authors report no conflicts of interest in this work.
Table 3 Delafloxacin unique characteristics compared to older quinolones
Characteristic Potential effect in clinical practice
Weak acid character Enhanced activity in low pH environments including inflammatory cells and infected tissues such 
as biofilm-associated infections, abscesses, skin and urinary infections
Dual target (gyrase and topoisomerase IV) Broader spectrum of action (gram-positive and gram-negative bacteria) and reduced selection 
of resistance
In vitro activity against MRSA, fluoroquinolone-
resistant gram-negative anaerobes
Empirical and targeted use in ABSSSI and potential use in other infections (e.g., respiratory 
infections, intra-abdominal infections, urinary tract infections)
Mild CYP3A4 induction No clinically relevant drug–drug interactions
Favorable safety profile in clinical trials Potential use in infections requiring prolonged treatment (e.g., >2 weeks)
Abbreviations: ABSSSI, acute bacterial skin and skin structure infections; CYP, cytochrome P450; MRSA, methicillin-resistant Staphylococcus aureus.
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